---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-008014"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T15:20:37.359884+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# DiaMedica FY2024 net loss $24.4M; cash $44.1M; preeclampsia data Q2 2025

## Summary
- Net loss $24.4M ($0.60/sh) vs $19.4M; R&D $19.1M, G&A $7.6M; no revenue.
- Cash $44.1M at Dec 31, 2024; runway into Q3 2026; operating cash burn $22.1M.
- Preeclampsia Phase 2 topline safety/efficacy data expected Q2 2025; dosing ongoing.
- ReMEDy2 AIS trial: DSMB cleared new IV dosing; interim analysis of first 200 patients expected H1 2026.
- Appointed Daniel J. O'Connor (former Ambrx CEO) to board in February 2025.

## SEC filing metadata
- accession: 0001437749-25-008014
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774925008014/0001437749-25-008014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774925008014/dmtp20250316_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-008014
- JSON: https://secwatch.observer/filing/0001437749-25-008014.json
- Plain text: https://secwatch.observer/filing/0001437749-25-008014.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.